Specific commensal bacteria activate vagal afferent neurons through GLP-1 receptor signaling, promoting neuroprotective pathways in the brainstem and substantia nigra. Targeted vagal stimulation combined with GLP-1 receptor agonists could enhance endogenous neuroprotection.
Curated pathway from expert analysis
graph TD
A["Commensal Bacteria<br/>Akkermansia and Lactobacillus"] --> B["SCFA Production<br/>Butyrate and Propionate"]
A --> C["Specialized Metabolites<br/>Indole-3-propionic acid and GABA precursors"]
B --> D["Intestinal Epithelium<br/>Metabolite Transport"]
C --> D
D --> E["Enteroendocrine L-cells<br/>Activation"]
E --> F["GLP-1 Release<br/>Incretin Hormone"]
F --> G["Vagal Afferent GLP1R<br/>Receptor Binding"]
G --> H["cAMP Signaling<br/>G-protein Activation"]
H --> I["Vagal Nerve<br/>Signal Transmission"]
I --> J["Brainstem Integration<br/>Nucleus Tractus Solitarius"]
J --> K["Neuroinflammation Reduction<br/>Anti-inflammatory Response"]
J --> L["Neuroprotection<br/>Synaptic Plasticity"]
K --> M["Disease Endpoint<br/>Reduced Neurodegeneration"]
L --> M
N["Therapeutic Intervention<br/>Probiotic Supplementation"] --> A
O["GLP-1 Receptor Agonists<br/>Pharmacological Target"] --> G
style N fill:#e1f5fe,color:#0d0d1a
style O fill:#e1f5fe,color:#0d0d1a
style M fill:#ffebee,color:#0d0d1a
Median TPM across 13 brain regions for GLP1R, BDNF from GTEx v10.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for GLP1R, BDNF.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention emphasize superior disease-modifying potential versus purely symptomatic benefits | emphasize superior disease-modifying potential versus purely symptomatic benefits | — no observation — | pending | 0.70 |
| If hypothesis is true, intervention provide personalized dosing recommendations and early detection of treatment response or adverse events | provide personalized dosing recommendations and early detection of treatment response or adverse events | — no observation — | pending | 0.70 |
| If hypothesis is true, intervention maintain GLP1R occupancy above 80% throughout the dosing interval | maintain GLP1R occupancy above 80% throughout the dosing interval | — no observation — | pending | 0.70 |